Characteristics and risk factors for antituberculosis drug-induced liver injury in a cohort of patients with cirrhosis in a tertiary referral university teaching hospital in Thailand
References
- World Health Organization. Global tuberculosis report 2015. Geneva: WHO Press; 2015.
- Thulstrup AM, Mølle I, Svendsen N, Sørensen HT. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect. 2000; 124:221–5.
- Kumar N, Kedarisetty CK, Kumar S, Khillan V, Sarin SK. Antitubercular therapy in patients with cirrhosis: Challenges and options. World J Gastroenterol. 2014; 20:5760–72.
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354:731–9.
- Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol. 2010; 7:543–56.
- Treeprasertsuk S, Huntrakul J, Ridtitid W, Kullavanijaya P, Björnsson ES. The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. Aliment Pharmacol Ther. 2010; 31:1200–7.
- Perwitasari DA, Atthobari J, Wilffert B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev. 2015; 47:222–8.
- Sobhonslidsuk A, Poovorawan K, Soonthornworasiri N, Pan-ngum W, Phaosawasdi K. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol. 2016; 16:135. doi:10.1186/s12876-016-0550-0.
- Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996; 77:335–40.
- Golemba AS, Ferreyra FG, Martearena RE, Achinelli FR, Rovai GB. Drug-induced hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast: cross-sectional study. Medwave. 2015; 15:e6135. doi:10.5867/medwave.2015.04.6135.
- Gülbay BE, Gürkan OU, Yıldız OA, Önen ZP, Erkekol FO, Baççıoğlu A, Acıcan T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006; 100:1834–42.
- Isa SE, Ebonyi AO, Shehu NY, Idoko P, Anejo-Okopi JA, Simji G, et al. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria. Int J Mycobacteriol. 2016; 5:21–6.
- Saha A, Shanthi FXM, Winston AB, Das S, Kumar A, Michael JS, Balamugesh T. Prevalence of hepatotoxicity from antituberculosis therapy: a five-year experience from South India. J Prim Care Community Health. 2016; 7:171–4.
- Sun Q, Zhang Q, Gu J, Sun W-W, Wang P, Bai C, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf. 2016; 25:908–17.
- Wondwossen A, Waqtola C, Gemeda A. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study. Int J Mycobacteriol. 2016; 5:14–20.
- Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, et al. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. Tuberculosis. 2015; 95:112–22.
- Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010; 132:81–6.
- Wang N-T, Huang Y-S, Lin M-H, Huang B, Perng C-L, Lin H-C. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc. 2016; 79:368–74.
- Park WB, Kim W, Lee KL, Yim J-J, Kim M, Jung YJ, et al. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. J Infect. 2010; 61:323–9.
- Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, Kwon YS. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis. 2014; 18:347–51.
- Cho Y-J, Lee SM, Yoo C-G, Kim YW, Han SK, Shim Y-S, Yim J-J. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology. 2007; 12:401–5.
- Sharma P, Tyagi P, Singla V, Bansal N, Kumar A, Arora A. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis. J Clin Exp Hepatol. 2015; 5:8–13.
- Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011; 89:806–15.
- Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; DILIN Study Group. Drug Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32:55–68. 20
- Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016; 63:e147–95.
- Wong W-M, Wu P-C, Yuen M-F, Cheng C-C, Yew W-W, Wong P-C, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000; 31:201–6.
- Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest. 1991; 99:465–71.
- Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients. PloS ONE. 2014; 9:e94271. doi:10.1371/journal.pone.0094271.
- Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1993; 53:529–35.
- Naidoo S, Evans D, Jong E, Mellet K, Berhanu R. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. S Afr Med J. 2015; 105:393–6.
- Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012; 2:260–70.
- Boeree, MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015; 191:1058–65.
- Pasipanodya, JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother. 2010; 54:2847–54.
Language: English
Page range: 65 - 74
Published on: Apr 30, 2019
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Keywords:
Related subjects:
© 2019 Passisd Laoveeravat, Nicha Wongjarupong, Chonlada Phathong, Cameron Hurst, Sombat Treeprasertsuk, Rungsun Rerknimitr, Roongruedee Chaiteerakij, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.